Background The prognostic nutritional index (PNI), estimated using serum albumin concentration and peripheral blood cell count, is a promising predictor of outcomes in patients with colon cancer. We aimed to show the difference in survival times based on adjuvant chemotherapy status in the low PNI group.Method The study enrolled 179 adult patients diagnosed with stage II colon cancer between January 2010 and September 2019. The PNI was calculated using the formula: 10 x serum albumin value (g/dL) + 0.005 x total lymphocyte count in the peripheral blood (per mm3). The ROC curve allowed us to validate the PNI for predicting survival with a threshold level of 47.255. The association between PNI and survival was evaluated with univariate and multivariate analysis. Subgroup analyses were conducted according to receipt of adjuvant chemotherapy (chemotherapy or no chemotherapy).Result The patients' mean age was 60.97,±11.53, and 67% were male. The cut-ff for the PNI obtained using the Roc curve method was 47.255. In 59.2% of the patients, the PNI was 47.255. In multivariate Cox regression analysis, a statistically significant difference was found between chemotherapy status and OS (mOS:168.36 m vs. 107.36 m, HR:0.39 (CI95%:0.16–0.94), p = 0.013, received and not received, respectively) and PFS (mPFS:168.36 m vs. 107.36 m, HR:0.38 (CI 95%:0.16–0.90), p = 0.014, received and no received, respectively).Conclusion The overall and progression-free survival duration of patients who did not get chemotherapy in the PNI subgroup was shorter than that of patients who did receive chemotherapy, according to the PNI established before surgery in stage II colon cancer patients.
Aim: To assess the prognostic role of the CA-125 elimination rate constant K (KELIM) score in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. Methods: A retrospective study was carried out including 117 patients with advanced-stage platinum-resistant/refractory ovarian cancer treated with liposomal doxorubicin ± bevacizumab. The KELIM score, calculated using CA-125 measurements within the first 100 days of chemotherapy, was used. Survival analyses were performed for overall survival (OS) and progression-free survival (PFS). Results: Higher KELIM scores were associated with a superior PFS and OS. Multivariate analysis confirmed the independent prognostic value of the KELIM score for OS. Validation cohorts showed consistent results. Conclusion: KELIM score may serve as a valuable prognostic marker for predicting OS and PFS in platinum-resistant/refractory ovarian cancer patients receiving second-line treatment. Prospective studies are needed for validation.
Pancreatic cancer is mostly metastaticat diagnosis. BReast CAncer gene (BRCA) mutations are associated with platinum sensitivity in metastatic pancreatic cancer. However, curative surgery and complete remission are infrequent. In this report, we present a 42-year-old female patient diagnosed with BRCA-mutated pancreatic cancer with liver metastases. After 12 cycles of FOLFIRINOX, liver metastases disappeared and the patient underwent pancreaticoduodenectomy. The patient has been followed in complete remission for 5 years. To the best of our knowledge, the presented case is the longest recurrence-free survival after platinum-based therapy in metastatic pancreatic cancer with BRCA mutation. Our case emphasizes that investigating BRCA gene mutations at the time of diagnosis can be life-saving in these patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.